oseltamivir has been researched along with Carcinoma, Hepatocellular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiu, CC; Hsiao, MH; Hsu, TC; Huang, PJ; Tzang, BS; Yow, JL | 1 |
| Shi, D; Song, X; Yan, B; Yang, D; Yang, J | 1 |
2 other study(ies) available for oseltamivir and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Potential of antiviral drug oseltamivir for the treatment of liver cancer.
Topics: Animals; Antiviral Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Female; Humans; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Invasiveness; Oseltamivir; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antiviral Agents; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Clopidogrel; Dose-Response Relationship, Drug; Female; Hepatocytes; Humans; Interleukin-6; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oseltamivir; Platelet Aggregation Inhibitors; RNA, Messenger; Ticlopidine | 2007 |